Literature DB >> 17582393

Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations.

Jing Du, Lan Yu, Lei Wang, Aiping Zhang, Anli Shu, Lingyun Xu, Mingsheng Xu, Yongyong Shi, Xingwang Li, Guoyin Feng, Qinghe Xing, Lin He.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17582393     DOI： 10.1016/j.cca.2007.04.027

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN： 0009-8981            Impact factor:   3.786


× No keyword cloud information.
  10 in total

1.  Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.

Authors:  Yu Cheng; Guo Wang; Wei Zhang; Lan Fan; Yao Chen; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2012-07-28       Impact factor: 2.953

2.  CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients.

Authors:  Wei Zhang; Yan-Zi Chang; Quan-Cheng Kan; Li-Rong Zhang; Zhi-Song Li; Hui Lu; Zhong-Yu Wang; Qin-Jun Chu; Jie Zhang
Journal:  Eur J Clin Pharmacol       Date:  2009-09-26       Impact factor: 2.953

3.  Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.

Authors:  Rui Liu; Zi-Yi Zhou; Yi-Bei Chen; Jia-Li Li; Wei-Bang Yu; Xin-Meng Chen; Min Zhao; Yuan-Qi Zhao; Ye-Feng Cai; Jing Jin; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

4.  CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.

Authors:  Yuan Gao; Li-rong Zhang; Qiang Fu
Journal:  Eur J Clin Pharmacol       Date:  2008-06-05       Impact factor: 2.953

5.  Serum alanine transaminase total bilirubin concentrations predict CYP3A activity as measured by midazolam and 1'-hydroxylation.

Authors:  Rui He; Yuhong Li; Jinguang Ruan
Journal:  Med Sci Monit       Date:  2015-02-04

6.  Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy.

Authors:  Jung Ran Choi; Jeong-Oh Kim; Dae Ryong Kang; Jung-Young Shin; Xiang Hua Zhang; Ji Eun Oh; Ji-Young Park; Kyoung-Ah Kim; Jin-Hyoung Kang
Journal:  Cancer Res Treat       Date:  2014-12-16       Impact factor: 4.679

7.  Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.

Authors:  Jing Liu; Zhiyu Chen; Hanmei Chen; Yingyong Hou; Weiqi Lu; Junyi He; Hanxing Tong; Yuhong Zhou; Weimin Cai
Journal:  Int J Mol Sci       Date:  2017-03-13       Impact factor: 5.923

8.  Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker.

Authors:  Miao Zhang; Zhiheng Yu; Xueting Yao; Zihan Lei; Kaijing Zhao; Wenqian Wang; Xue Zhang; Xijing Chen; Dongyang Liu
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

9.  A new donors' CYP3A5 and recipients' CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients.

Authors:  Yuan Liu; Tao Zhang; Xiaoqing Zhang; Ling Ye; Haitao Gu; Lin Zhong; Hongcheng Sun; Chenlong Song; Zhihai Peng; Junwei Fan
Journal:  Oncotarget       Date:  2017-07-26

10.  The effect of CYP1A2 gene polymorphism on the metabolism of theophylline.

Authors:  Shijuan Xiong; Lingling Li
Journal:  Exp Ther Med       Date:  2017-10-30       Impact factor: 2.447
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.